Customer Story • Video
Biomarkers of Response for Clinical Trials
Welcome to the eighth in our series of case studies showcasing Metabolon clients’ achievements in discovery, preclinical, and clinical research.
Here, our client developed a patient-friendly way to show the efficacy of potential therapies for a severe form of liver inflammation – nonalcoholic steatohepatitis (NASH) – which has no FDA-approved treatments. This group of 22 potential blood biomarkers could replace the need for costly imaging or invasive liver biopsies in clinical trials for this disease.